Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.69 |
| ▸ | GAA | P10253 | 6/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | HPGD | P15428 | 3/20 | 0.69 |
| ▸ | HTT | P42858 | 3/20 | 0.69 |
| ▸ | PKM | P14618 | 2/20 | 0.69 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.69 |
| ▸ | GLA | P06280 | 2/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | KIF11 | P52732 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 2/20 | 0.57 |
| ▸ | HTR3A | P46098 | 1/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30183620 | 1.00 | ALDH1A1 (0.69) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL2115896 | 0.89 | KDM4E (0.58) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL4252129 | 0.84 | KDM4E (0.64) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL2116506 | 0.83 | HTR3A (0.62) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL4254017 | 0.82 | KDM4E (0.54) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL6306378 | 0.82 | KMT2A (0.77) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL30414309 | 0.82 | KMT2A (0.77) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL11798445 | 0.82 | ALDH1A1 (0.67) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL27202941 | 0.82 | ALDH1A1 (0.61) | ALDH1A1KDM4EGAAKMT2AHPGD | |
| SCHEMBL2115751 | 0.80 | ALDH1A1 (0.78) | ALDH1A1KDM4EGAAKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081521-B1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LTD (IN) | 2025-12-10 | — | — | EP | disclosed |
| CN-115605476-B | Substituted tricyclic compounds | 鲁宾有限公司 | 2024-05-24 | — | — | CN | disclosed |
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. | 2024-04-25 | — | — | US | disclosed |
| WO-2024050370-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2024050370-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | 1CBIO, INC. (US) | 2024-03-07 | — | — | WO | disclosed |
| WO-2023096915-A1 | MULTICYCLIC COMPOUNDS | SLAP PHARMACEUTICALS LLC (US) | 2023-06-01 | — | — | WO | disclosed |
| US-20230119316-A1 | Substituted Tricyclic Compounds | LUPIN LIMITED (IN) | 2023-04-20 | — | — | US | disclosed |
| CN-115605476-A | Substituted tricyclic compounds | 鲁宾有限公司（IN） | 2023-01-13 | — | — | CN | disclosed |
| EP-4081521-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | Lupin Limited (IN) | 2022-11-02 | — | — | EP | disclosed |
| WO-2021130731-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS | LUPIN LIMITED (IN) | 2021-07-01 | — | — | WO | disclosed |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. | 2016-02-11 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765773-B2 | Substituted hydroxamic acids and uses thereof | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2014-07-01 | — | — | US | disclosed |
| WO-2012054332-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012054332-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094997-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ALDH1A1 298/4885KDM4E 769/4885GAA 285/4885 |
| US-20160039789-A1 | SUBSTITUTED HYDROXAMIC ACIDS AND USES THEREOF | HDAC6, HDAC1, HDAC5 | ALDH1A1 298/4885KDM4E 769/4885GAA 285/4885 |
| US-20230119316-A1 | Substituted Tricyclic Compounds | SOS1, RSU1, KSR1 | ALDH1A1 3322/4885KDM4E 4661/4885GAA 2659/4885 |
| US-20240132449-A1 | HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF | PARP1, PARP11, PARP12 | ALDH1A1 290/4885KDM4E 1701/4885GAA 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.